MedTrace Logo

A Multiple-Ascending Dose Study in Type 2 Diabetes Mellitus Patients

NCT01253278 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2011-06-10

No results posted yet for this study

Summary

The study drug LY2393910 is being evaluated as a possible treatment for diabetes. The primary purpose of a patient's participation in this study is to help answer the following research question(s), and not to provide treatment for diabetes:

* The safety of LY2393910 and any side effects that might be associated with it following 2 weeks of doses
* How long it takes the body to absorb and remove LY2393910 following dosing over 2 weeks
* How daily dosing of LY2393910 affects blood levels of sugar (glucose), insulin and other naturally occurring substances in your body
* How daily dosing of LY2393910 affects the cells that produce insulin
* Any differences in the above between LY2393910 taken as daily doses in the morning or in the evening

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

LY2393910

as capsules, administered orally once daily for two weeks

DRUG

Placebo

as capsules, administered orally once daily for two weeks

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01253278 on ClinicalTrials.gov